Goldman Sachs' (GS) investment arm, Goldman Sachs Asset Management, has agreed to acquire drugmaker Synthon from private equity group BC Partners for more than 2 billion euro ($2.10 billion), the Financial Times reported Monday, citing people familiar with the matter.
Goldman Sachs did not immediately respond to a request for comment from MT Newswires.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.